Jian Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jian Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Gang Hao
Department of Pathophysiology, Capital Medical University, Beijing, China
1 shared publicationGuobin Miao
Department of Internal Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
1 shared publicationHuiling An
Department of Internal Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
1 shared publication- Lin Zhang
Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
1 shared publication Lingqiao Lu
Department of Pathophysiology, Capital Medical University, Beijing, China
1 shared publicationMiaobing Liu
Department of Internal Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- RetractedOpen Access
- 5 July 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e68747
Relationship between the Autoantibody and Expression of β3-Adrenoceptor in Lung and Heart
Evidences suggest that β3-adrenoceptor (β3-AR) plays an important role in heart failure (HF), although no data is reported indicating how these effects may change with the increasing age. Pulmonary congestion and edema are the major life-threatening complications associated with HF. The purpose of this study is to explore the relationship between the anti-β3-AR autoantibody and the expression of β3-AR in the lungs and heart for both aged patients and rats with HF. Synthetic β3-AR peptides served as the target antigens in ELISA were used to screen the anti-β3-AR autoantibody in aged patients and rats. Two aged rat models were constructed based on aortic banding and sham-operation. The expression of β3-AR mRNA and protein in the lung and heart was measured in intervention and non-intervention groups by Western blot analysis at the baseline, 5th, 7th, 9th and 11th week, respectively. The frequency and titer of anti-β3-AR autoantibody in aged patients and rats with HF were higher than those in the control group (p3-AR mRNA and protein in pulmonary tissues decreased continually from the 7th week (pth week. The expression of β3-AR in myocardial tissues continued to increase after the 9th week (p3-AR mRNA and protein in the BRL group [HF group with BRL37344 (4-[-[2-hydroxy-(3-chlorophenyl)ethyl-amino] phenoxyacetic acid) (a β3-AR agonist) injection] was positively correlated with BRL37344 when compared with non-BRL group (HF group without BRL37344 injection) (p3-AR autoantibody was detected in aged patients and rats with HF. The expression of β3-AR mRNA and protein in pulmonary tissues decreased continually, and began earlier than in the heart, but its expression in myocardial tissues increased continually and could be further promoted by β3-AR agonist.
- 5 July 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e68747
RetractedOpen AccessRelationship between the Autoantibody and Expression of β3-Adrenoceptor in Lung and Heart
Evidences suggest that β3-adrenoceptor (β3-AR) plays an important role in heart failure (HF), although no data is reported indicating how these effects may change with the increasing age. Pulmonary congestion and edema are the major life-threatening complications associated with HF. The purpose of this study is to explore the relationship between the anti-β3-AR autoantibody and the expression of β3-AR in the lungs and heart for both aged patients and rats with HF. Synthetic β3-AR peptides served as the target antigens in ELISA were used to screen the anti-β3-AR autoantibody in aged patients and rats. Two aged rat models were constructed based on aortic banding and sham-operation. The expression of β3-AR mRNA and protein in the lung and heart was measured in intervention and non-intervention groups by Western blot analysis at the baseline, 5th, 7th, 9th and 11th week, respectively. The frequency and titer of anti-β3-AR autoantibody in aged patients and rats with HF were higher than those in the control group (p3-AR mRNA and protein in pulmonary tissues decreased continually from the 7th week (pth week. The expression of β3-AR in myocardial tissues continued to increase after the 9th week (p3-AR mRNA and protein in the BRL group [HF group with BRL37344 (4-[-[2-hydroxy-(3-chlorophenyl)ethyl-amino] phenoxyacetic acid) (a β3-AR agonist) injection] was positively correlated with BRL37344 when compared with non-BRL group (HF group without BRL37344 injection) (p3-AR autoantibody was detected in aged patients and rats with HF. The expression of β3-AR mRNA and protein in pulmonary tissues decreased continually, and began earlier than in the heart, but its expression in myocardial tissues increased continually and could be further promoted by β3-AR agonist.